Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 2 1

Status

Recruiting 2

Sponsor Class

OTHER_GOV 1OTHER 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 1Genitourinary 1

Conditions

Prostate CA 1Lymphoma, Follicular 1Cognitive Dysfunction 1Alzheimer Disease 1

Interventions

pembrolizumab 1258Specimen Handling 864Carboplatin 824Magnetic Resonance Spectroscopy 806Cyclophosphamide 798Cisplatin 719Nivolumab 660Paclitaxel 635Gemcitabine 570Radiotherapy 570Biopsy 526Bevacizumab 467Dexamethasone 441fludarabine 403Docetaxel 375venetoclax 369Oxaliplatin 363Capecitabine 355Fluorouracil 354atezolizumab 337Rituximab 333durvalumab 332Doxorubicin 316Pemetrexed 306Radiosurgery 304Drug Therapy 300Ipilimumab 296Standard of Care 288Etoposide 283Radiation 277

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × fasudil × 1 year × Clear all
NCT06362707 2026-05-04

FEAD

Helse Stavanger HF

Phase 2 Recruiting
200 enrolled
Lymphoid

Alzheimer Disease, Lymphoma, Follicular, Cognitive Dysfunction

NCT06861192 2025-11-18

Clinical Study of Fasudil Hydrochloride and PD1 Inhibitor Combined With Androgen Deprivation in Neoadjuvant Therapy of Prostate Cancer

Zhongda Hospital

Phase 2/3 Recruiting
83 enrolled
Genitourinary

Prostate CA

Data powered by HemOnc (CC BY 4.0) Colophon âš¡